Robert Taylor Nelsen

Robert Nelsen is a Co-Founder and serves as a Managing Director at ARCH Venture Partners. He is a Co-Founder and serves as Member of the Board of Director at Vir Biotechnology and Brii Biosciences. He is a Board Member at Beam Therapeutics. He also serves as a member of Agios Pharmaceuticals board of directors since December 2007. Nelsen was a co-founder of ARCH Venture Partners, a venture capital firm, and has served in various capacities for ARCH and affiliated entities since 1986. Nelson is currently a managing director of ARCH Venture Corporation. Nelsen has played a significant role in the early sourcing, financing and development of more than 30 companies. Nelsen is a director of Sapphire Energy, Inc., Ensemble Therapeutics Corporation, Juno Therapeutics, Inc., Syros Pharmaceuticals Inc., Arivale Inc., Denali Therapeutics, and Faraday Pharmaceuticals, Inc., among other companies, and previously served on the boards of Bellerophon Therapeutics, Inc., Fate Therapeutics, Inc., Elixir Pharmaceuticals, Inc., Ikaria Inc., Kythera Biopharmaceuticals, Inc., NeurogesX, Inc., Sage Therapeutics, Inc., and entities affiliated with deCode Genetics, Inc., among others. Nelsen was previously a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and a director of the National Venture Capital Association. Nelsen previously served Nelsen received a B.S. with majors in biology and economics from the University of Puget Sound and an M.B.A. from the University of Chicago. He is Board of Director at Grail (Biotechnology).